Compound ID | 1505
Class: Glycopeptide
| Agent Type: | Natural product; Direct acting; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | Cell wall synthesis inhibitor |
| Target Pathogen: | Broad Gram-positive activity including anaerobes |
| Description: | Natural product from Amycolatopsis orientalis (formerly Streptomyces orientalis |
| Institute where first reported: | FDA, USA; ANI Pharmaceuticals |
| Year first mentioned: | 1956 |
| Highest development stage: | Approved by FDA in 1986 |
| Development status: | Approved |
| Reason dropped: | Other formulations were discontinued |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/14969 |
| Guide to Pharmacology: | vancomycin |
| Citations: |
|